このページの翻訳は実験的なもので、現在開発中です。お待ちしております

OssDsign 過去の業績

過去基準チェック /06

OssDsignの収益は年間平均-9.6%の割合で減少していますが、 Medical Equipment業界の収益は年間増加しています。収益は年間17% 41.1%割合で増加しています。

主要情報

-8.8%

収益成長率

36.2%

EPS成長率

Medical Equipment 業界の成長	6.2%
収益成長率	42.6%
株主資本利益率	-50.6%
ネット・マージン	-92.2%
次回の業績アップデート	05 Nov 2024

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Aug 23

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

Aug 06

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

Jun 19

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

Mar 19

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Aug 19

収支内訳

OssDsign の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。

収益と収入の歴史

OM:OSSD 収益、費用、利益 ( )SEK Millions
日付	収益	収益	G+A経費	研究開発費
30 Jun 24	123	-114	149	26
31 Mar 24	118	-118	145	27
31 Dec 23	112	-130	143	29
30 Sep 23	97	-109	131	29
30 Jun 23	83	-95	113	40
31 Mar 23	71	-99	142	8
31 Dec 22	57	-99	113	25
30 Sep 22	46	-96	111	17
30 Jun 22	38	-93	115	0
31 Mar 22	33	-95	107	0
31 Dec 21	32	-94	104	0
30 Sep 21	29	-90	100	0
30 Jun 21	27	-92	100	0
31 Mar 21	23	-90	94	0
31 Dec 20	25	-85	92	0
30 Sep 20	24	-89	96	0
30 Jun 20	22	-89	97	0
31 Mar 20	22	-85	94	0
31 Dec 19	18	-84	90	0
30 Sep 19	18	-72	80	0
30 Jun 19	20	-66	73	0
31 Mar 19	21	-62	68	0
31 Dec 18	21	-56	63	0
31 Dec 17	16	-63	52	0

質の高い収益: OSSDは現在利益が出ていません。

利益率の向上: OSSDは現在利益が出ていません。

フリー・キャッシュフローと収益の比較

過去の収益成長分析

収益動向: OSSDは利益が出ておらず、過去 5 年間で損失は年間9.6%の割合で増加しています。

成長の加速: OSSDの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: OSSDは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 41.1% ) と比較することは困難です。

株主資本利益率

高いROE: OSSDは現在利益が出ていないため、自己資本利益率 ( -52.77% ) はマイナスです。

OssDsign 過去の業績

過去 基準チェック /06

主要情報

最近の業績更新

Second quarter 2024 earnings: EPS misses analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

Recent updates

OssDsign AB (publ) (STO:OSSD) Just Reported Earnings, And Analysts Cut Their Target Price

Second quarter 2024 earnings: EPS misses analyst expectations

We Think OssDsign (STO:OSSD) Can Afford To Drive Business Growth

OssDsign AB (publ) Approves Election of Christer Fåhraeus as Ordinary Board Member

Increases to OssDsign AB (publ)'s (STO:OSSD) CEO Compensation Might Cool off for now

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on Jun 04, 2024

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ) to Report Fiscal Year 2023 Final Results on May 22, 2024

No longer forecast to breakeven

Getting In Cheap On OssDsign AB (publ) (STO:OSSD) Is Unlikely

OssDsign AB (publ.) Appoints Tom Buckland as Chief Technical Officer

New minor risk - Share price stability

Forecast breakeven date moved forward to 2024

OssDsign AB (publ), Annual General Meeting, May 21, 2024

Consensus EPS estimates fall by 30%, revenue upgraded

Forecast breakeven date moved forward to 2024

OssDsign AB (publ.) Announces 12-Month Data from the Clinical Study Top Fusion

OssDsign AB (publ) to Report Q3, 2024 Results on Nov 05, 2024

OssDsign AB (publ) Reports Exceptional Data from the Clinical Study TOP FUSION

Ossdsign AB (Publ) Provides Revenue Guidance for the Fourth Quarter of 2023

An Unknown buyer acquired 7.6% stake in OssDsign AB (publ) (OM:OSSD).

OssDsign AB (publ) to Report Fiscal Year 2023 Results on Feb 06, 2024

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 150.000003 million.

OssDsign AB (publ) Announces All Activities Pertaining to the Patient-Specific Cranial Implant Business Will Be Discontinued in A Responsible Manner by the End of December 2023

OssDsign Receives FDA Clearance for A New Major Indication

Consensus EPS estimates fall by 15%

Consensus estimates of losses per share improve by 14%

Second quarter 2023 earnings released: kr0.30 loss per share (vs kr0.40 loss in 2Q 2022)

Here's Why We're Not Too Worried About OssDsign's (STO:OSSD) Cash Burn Situation

Forecast breakeven date moved forward to 2024

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Full year 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

No longer forecast to breakeven

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

Full year 2022 earnings released: kr1.70 loss per share (vs kr1.94 loss in FY 2021)

OssDsign AB (publ) to Report Fiscal Year 2022 Results on Feb 21, 2023

Forecast to breakeven in 2025

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 65.63568 million.

Third quarter 2022 earnings: EPS and revenues exceed analyst expectations

Second quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

OssDsign AB (publ) Ordinary Shares to Be Deleted from OTC Equity

High number of new directors

Is OssDsign (STO:OSSD) In A Good Position To Deliver On Growth Plans?

OssDsign AB (publ) Elects Jill Shiaparelli as Board Member

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target decreased to kr14.00

Insufficient new directors

Consensus revenue estimates fall by 16%

Chief Executive Officer recently bought kr133k worth of stock

Chief Executive Officer recently bought kr133k worth of stock

Full year 2021 earnings: EPS and revenues exceed analyst expectations

Full year 2021 earnings: EPS and revenues exceed analyst expectations

OssDsign AB (publ), Annual General Meeting, Jun 02, 2022

Insufficient new directors

OssDsign AB (publ.) Receives Approval to Establish Clinical Registry in the U.S. to Collect Real-World Data on OssDsign Catalyst

Forecast to breakeven in 2024

OssDesign AB (Publ.) Announces Updated Clinical Data from A Long-Term Follow-Up of the Company's Innovative Product OssDsign Cranial PSI, Which Is Used in the Treatment of Cranial Bone Defects

Chief Executive Officer recently bought kr124k worth of stock

Third quarter 2021 earnings released: kr0.30 loss per share (vs kr1.10 loss in 3Q 2020)

Second quarter 2021 earnings released: kr0.40 loss per share (vs kr1.30 loss in 2Q 2020)

Independent Chairman of the Board recently bought kr150k worth of stock

Consensus EPS estimates increase to -kr3.00

Price target decreased to kr17.33

Chief Executive Officer recently bought kr210k worth of stock

Chief Executive Officer recently bought kr388k worth of stock

Ossdsign AB (Publ) Announces Innovative Synthetic Bone Graft Outperforms a Comparable Device in Bone Formation Following Spinal Fusion Surgery

Chief Financial Officer recently bought kr214k worth of stock

OssDsign AB (publ) has completed a Follow-on Equity Offering in the amount of SEK 240.506091 million.

過去基準チェック /06